Members of the STAT family of transcriptional regulators modulate the expression of a variety of gene products that promote cell proliferation, survival and transformation. Although initially identi®ed as mediators of cytokine signaling, the STAT proteins are also activated by, and thus may contribute to the actions of, polypeptide growth factors. To de®ne the mechanism by which these factors activate STATs, we examined the process of Stat3 activation in Balb/c-3T3 ®broblasts treated with platelet-derived growth factor (PDGF). As STATs are activated by tyrosine phosphorylation, and as PDGF receptors are ligand-activated tyrosine kinases, we considered the possibility that Stat3 interacts with and is phosphorylated by PDGF receptors. We ®nd that Stat3 associates with PDGF b receptors in both the presence and, surprisingly, the absence of PDGF. Moreover, Stat3 was phosphorylated on tyrosine in PDGF b receptor immunoprecipitates of PDGF-treated but not untreated cells. Although required, receptor activation was insucient for Stat3 activation. When added to cells in combination with a pharmacologic agent (PD180970) that speci®cally inhibits the activity of Src family tyrosine kinases, PDGF did not activate Stat3 as monitored by electrophoretic mobility shift assay. PD180970 did not aect MAPK activation by PDGF or the JAK-dependent activation of Stat3 by interleukin-6. The necessity of Src activity for Stat3 activation by PDGF was further evidenced by data showing the presence of Src in complexes containing both Stat3 and PDGF b receptors in PDGF-treated cells. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated. Additional data demonstrate that Src kinase activity is also required for PDGF stimulation of DNA synthesis in density-arrested cells.
Introduction
Interaction of extracellular polypeptide hormones with speci®c cell-associated receptor tyrosine kinases (RTKs) results in the activation of numerous signaling pathways that convey information from the cell membrane to the nucleus (Seedorf, 1995; Heldin, 1996) . In response to ligand binding, RTKs dimerize, become enzymatically active, and phosphorylate speci®c tyrosine residues in their intracellular domains. Sequences encompassing these phosphotyrosines serve as recognition sites for the SH2 domains of a variety of signaling molecules, and consequent association of these proteins with activated receptors results in their phosphorylation and activation or, in the case of`adaptors,' their coupling to downstream mediators (Marengere and Pawson, 1994; Schlessinger, 1994) . SH2 domain-containing signaling molecules include phospholipase Cg, phosphatidylinositol-3 kinase, GRB2, and c-Src, and phosphopeptide mapping and mutational analysis of RTKs has shown that speci®c signaling molecules recognize speci®c phosphotyrosine-containing sequences (Seedorf, 1995; Heldin, 1996) . Once bound to receptors, signaling molecules induce a multiplicity of events that lead to the expression of genes whose products act in an integrated fashion to promote the proliferation, dierentiation or survival of target cells; such events include metabolism of membrane phospholipids, initiation of serine/threonine kinase cascades, and activation of small GTP-binding proteins such as Ras, Rac and Rho.
One well-characterized RTK-activated response that exempli®es membrane-to-nuclear signaling is the Ras/ Raf kinase/MAPK (mitogen-activated protein kinase) pathway (Marais and Marshall, 1996) . Activation of this pathway is initiated by interaction of ligandbound receptors with GRB2 or other adaptor, requires intermediary factors such as SOS, and culminates in the activation of several nuclear transcription factors. Another, although less well understood, process linking RTKs to gene expression involves the STAT (Signal Transducer and Activator of Transcription) family of transcriptional regulators Ihle et al., 1995) . To date, this family consists of seven members, all of which contain a single SH2 domain (Darnell, 1997) . Although originally identi®ed as mediators of cytokine signaling (Ihle et al., 1995) , the STAT proteins are also activated by polypeptide hormones such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and colony-stimulating factor 1 (Schindler and Darnell, 1995; Leaman et al., 1996) . PDGF, for example, has been shown to activate Stats 1, 3, 5 and 6 in a number of dierent cell types (Wagner et al., 1990; Patel et al., 1996; Valgeirsdottir et al., 1998) . Activation of STATs requires phosphorylation of cytosolic STAT monomers at a speci®c tyrosine residue and consequent formation of STAT homo-or heterodimers; phosphorylated dimers then translocate to the nucleus where they interact with speci®c DNA response elements (Darnell, 1997) . The STAT proteins, therefore, function as both cytoplasmic signaling molecules and nuclear transcription factors and, in contrast to the multi-component Ras/Raf/MAPK pathway, represent a direct connection between the cell membrane and the nucleus. Although tyrosine phosphorylation is sucient for STAT activation (de®ned here in the classical sense as acquisition of DNA binding activity), it is noted that full transcriptional activation of these proteins also requires their phosphorylation at speci®c serine residues (Boulton et al., 1995; Turkson et al., 1998) .
The STAT proteins are key players in cytokine signaling, and may also participate in responses elicited by polypeptide hormones (Schindler and Darnell, 1995; Leaman et al., 1996) . For example, via their capacity to modulate the expression of genes encoding growth-regulatory proteins such as cyclin D1 (Matsumura et al., 1999) , p21 WAF1 (Chin et al., 1996) and c-Fos (Hayes et al., 1987; Wagner et al., 1990) , the STAT proteins may contribute to the proliferative response induced by hormones such as EGF and the potent ®broblast mitogen, PDGF. Given the importance of the STAT proteins in a variety of systems (Akira, 1999) , numerous studies have focused on the mechanism of STAT activation, and for cytokines, this mechanism has been well-characterized (Ihle et al., 1995; Darnell 1997) . Cytokine receptors lack intrinsic tyrosine kinase activity, and in cells treated with cytokines (e.g., interleukins or interferons), the STAT proteins are phosphorylated, and thus activated, by members of the JAK (Janus kinase) family of tyrosine kinases. Current models of cytokine signaling propose that JAKs (Jak1, Jak2, Jak3 and Tyk2) are constitutively associated with cytokine receptors and, in response to ligand-induced receptor oligimerization, are juxtaposed, cross-phosphorylated and activated. Activated JAKs phosphorylate cytokine receptors, thus creating docking sites for STAT SH2 domains, and receptor-associated STATs are then tyrosine phosphorylated by JAKs. In some situations, autophosphorylated JAKs may themselves serve as STAT binding sites (Fujitani et al., 1997) .
With regard to STAT activation by polypeptide hormones, the mechanism is less clear, and studies focusing on STAT activation by PDGF suggest three potential mechanisms. Vignais and Gilman (1999) , for example, showed that puri®ed PDGF receptor (the b form) phosphorylated recombinant Stat1 in a PDGFdependent manner, and thus propose that Stat1 is directly phosphorylated and activated by RTKs. Data demonstrating in vitro phosphorylation of Stat1 and Stat3 by activated EGF receptors support this premise (Park et al., 1996) . Other ®ndings, however, suggest that PDGF-induced STAT phosphorylation is mediated by JAKs. For example, Jak1, Jak2 and Tyk2 are activated in cells in response to PDGF (Vignais et al., 1996) , and the capacity of antioxidants to inhibit both JAK activation and Stat1 and Stat3 activation in PDGF-stimulated cells establishes a link between these events (Simon et al., 1998) . In addition to JAKs, PDGF also activates the non-receptor tyrosine kinase c-Src (Ralston and Bishop, 1985; Gould and Hunter, 1988) , and elevated STAT activity has been observed in cells expressing activated c-Src or its oncogenic counterpart, v-Src (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997; Garcia et al., 1997) . Also indicative of Src participation in PDGFinduced STAT activation are studies showing abrogation of this response by dominant-negative c-Src (Cirri et al., 1997) and by mutation of the Src binding sites on the PDGF b receptor (Valgeirsdottir et al., 1998) . As a further consideration, it is noted that more than one kinase may contribute to or be required for STAT activation by PDGF or, as suggested by Vignais and Gilman (1999) , dierent kinases may mediate activation of dierent STAT proteins. Consistent with a role for c-Src in receptor-mediated Stat3 activation, recent studies have shown that interleukin-3 induces Stat3 tyrosine phosphorylation by a mechanism requiring Src but not JAK family kinases (Chaturvedi et al., 1998) .
As a means of more precisely de®ning the mechanism of STAT activation by polypeptide hormones, we examined Stat3 activation in normal mouse ®broblasts stimulated with PDGF. Our data demonstrate the in vivo association of Stat3 with PDGF b receptors, and show, surprisingly, that this interaction occurs in the absence of mitogenic stimulation. Phosphorylation of Stat3 at tyrosine and binding of Stat3 to DNA, however, required exposure of cells to PDGF, and Stat activation by PDGF was precluded by inhibition of Src kinase activity. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated.
Results

Activation of Stat1 and Stat3 by PDGF in fibroblasts
Stats 1 and 3 were initially detected in ®broblasts as an activity (termed the sis-inducible factor [SIF] ) that bound a conserved sequence in the c-fos promoter (termed the sis-inducible element [SIE] ) in response to v-sis, the oncogenic form of the BB isoform of PDGF (Hayes et al., 1987) . Subsequent studies demonstrated that SIF activity consisted of three complexes termed SIF-A, -B and -C which were composed of Stat3 homodimers, Stat1/3 heterodimers and Stat1 homodimers, respectively (Sadowski et al., 1993; Zhong et al., 1994) . In preliminary experiments, we veri®ed the induction of these complexes in PDGF-treated ®bro-blasts. Density-arrested Balb/c-3T3 cells were stimulated with 10 ng/ml PDGF for 10 min at 378C, and whole-cell extracts were analysed by EMSA using the hSIE probe (see Materials and methods). As shown in Figure 1a , three hSIE-binding complexes were apparent in PDGF-treated cells. The slowest migrating complex was supershifted by antibody to Stat3 but was unaected by antibody to Stat1, and thus consists of Stat3 homodimers (i.e., is SIF-A). Conversely, the fastest migrating complex was blocked by antibody to Stat1 and essentially unaected by antibody to Stat3, and thus is composed of Stat1 homodimers (i.e., is SIF-C). The complex with the intermediate mobility apparently represents Stat1/Stat3 heterodimers (i.e., is SIF-B), as it was supershifted/blocked in part by antibodies to both Stat1 and Stat3. The incomplete supershift/loss of this complex may simply re¯ect the diminished capacity of the antibodies to recognize their respective targets in heterodimeric complexes (Simon et al., 1998) . In contrast to Stat1/3 and Stat1/1 activities, which were undetectable in the absence of PDGF, a low level of Stat3/3 activity was observed in unstimulated cells; the reason for this is not known. To examine the kinetics of STAT induction, densityarrested Balb/c-3T3 cells were exposed to PDGF for various times, and whole-cell lysates were analysed by EMSA as above. The DNA-binding activities of Stat3/ 3, Stat1/3 and Stat1/1 were increased within 5 min of stimulation, and were highest at 10 ± 30 min ( Figure  1b ). Stat1/1 activity was induced to a lesser extent than were Stat3/3 and Stat1/3 activities, and all activities were reduced substantially at 4 h. Thus, these activities are rapidly and transiently induced by PDGF in ®broblasts. Activation of the STAT proteins requires their phosphorylation at speci®c tyrosine residues (Darnell, 1997) , and experiments assessing the time course of Stat3 phosphorylation at Tyr 705 demonstrated kinetics similar to those described in Figure 1b . In these experiments, whole-cell extracts were immunoprecipitated with antibody to Stat3, and precipitated material was immunoblotted with an antibody that speci®cally recognizes Stat3 phosphorylated at Tyr 705. Tyr 705-phosphorylated Stat3 was not detected in quiescent cells, but was readily apparent within 5 min of PDGF addition to cells ( Figure 1c , top panel). Levels of phosphorylated Stat3 peaked at *30 min and were markedly diminished by 3 h. Changes in the amount of Stat3 phosphorylation did not re¯ect changes in the amount of Stat3 protein, which remained constant throughout the duration of the experiment (bottom panel).
In response to stimulus and consequent phosphorylation and dimerization, the STAT proteins translocate to the nucleus (Darnell, 1997). As a further means of assessing STAT activation in PDGF-treated ®bro-blasts, nuclear extracts prepared at various times after stimulation were immunoblotted with antibody to Stat3. Stat3 was barely detectable in nuclear extracts of unstimulated cells; amounts of nuclear Stat3 increased within 1 min of PDGF addition, and were maximal at 10 ± 30 min ( Figure 1d , bottom panel). Thus, the accumulation of Stat3 in the nucleus coincides with the appearance of Stat3 DNA binding activity ( Figure 1b ). Similar kinetics were observed when nuclear extracts were immunoblotted with antibody to Tyr 705-phosphorylated Stat3 (Figure 1d , top panel). These ®ndings indicate that in response to PDGF, Stat3 translocates from the cytosol to the nucleus, and that Stat3 in the nucleus is phosphorylated on tyrosine. Collectively, the data in Figure 1 show that PDGF induces the tyrosine phosphorylation, nuclear translocation, and DNA-binding activity of STAT proteins in quiescent Balb/c-3T3 cells. In addition, transient transfection assays using a luciferase reporter plasmid (Turkson et al., 1998) containing multiple copies of the acute phase response element, which binds Stat3, demonstrated that the increase in Stat3 DNA-binding activity induced by PDGF was accompanied by an approximate ®vefold elevation in Stat3 transcriptional activity (data not shown).
Stat3 phosphorylation on tyrosine 705 at 48C
As described above, tyrosine phosphorylated Stat3 appears in the nucleus within 1 min of addition of PDGF to cells. The rapidity of this response suggests that Stat3 is a direct substrate of the PDGF receptor or of a kinase closely associated with the receptor. Autophosphorylation of the PDGF receptor occurs at 48C (Harrington et al., 1985) , as does the phosphorylation of PDGF receptor substrates such as phospholipase Cg (Wahl et al., 1989) . To determine if Stat3 is also phosphorylated at 48C, pre-chilled quiescent cultures were treated with or without PDGF for 10 min on ice. Total cell lysates were immunoprecipitated with antibody to Stat3, and precipitated material was immunoblotted with antibody to Tyr 705-phosphorylated Stat3 (Figure 2a , top panel) or, to ensure that equal amounts of Stat3 were analysed, with antibody to Stat3 (bottom panel). The results of this experiment clearly show that Stat3 is phosphorylated at tyrosine 705 at 48C in the presence but not the absence of PDGF. Tyrosinephosphorylated Stat3 did not, however, translocate to the nucleus at 48C (data not shown).
Association of Stat3 with PDGF b receptors in quiescent cultures
The capacity of PDGF to induce Stat3 tyrosine phosphorylation at 48C suggests that Stat3 is in close proximity to the PDGF receptor. To assess Stat3 interaction with PDGF receptors, quiescent Balb/c-3T3 cells were incubated in the presence or absence of PDGF for 10 min at 48C; whole-cell extracts were immunoprecipitated with antibody to the PDGF b receptor, and immunoprecipitated material was immunoblotted with antibody to Stat3. As shown in Figure 2b , antibody to the PDGF b receptor coprecipitated Stat3 from extracts of both untreated and PDGF-treated cells; the amount of Stat3 present in PDGF b receptor immune complexes was not substantially increased by PDGF treatment. These results show that Stat3 interacts with the PDGF b receptor in vivo, and that this association occurs in the absence of PDGF stimulation. The latter ®nding is somewhat unexpected, but is in agreement with a recent report showing ligand-independent binding of STAT proteins to ErbB1 (EGF) receptors (Olayioye et al., 1999) . 
PDGF-dependent tyrosine phosphorylation of Stat3
The observation that activation of Stat3 requires PDGF stimulation (Figure 1 ), whereas association of Stat3 with the PDGF b receptor does not (Figure 2b ), suggests that receptor-associated Stat3 is not phosphorylated on tyrosine, and therefore is inactive, in the absence of PDGF. To test this hypothesis, cells were either left untreated or exposed to PDGF for 5 or 10 min at 378C; whole-cell extracts were immunoprecipitated with antibody to the PDGF b receptor and immunoblotted with antibody to Stat3 or Tyr 705-phosphorylated Stat3. Essentially comparable levels of Stat3 were present in PDGF b immunoprecipitates of both stimulated and unstimulated cells ( To determine if the kinase responsible for Stat3 phosphorylation in PDGF-treated cells was present in Stat3/PDGF b receptor complexes, extracts of cells treated with or without PDGF for 10 min at 378C were immunoprecipitated with antibody to the PDGF b receptor or to Tyr 705-phosphorylated Stat3; precipitated material was incubated with [g-32 P]ATP and resolved by SDS ± PAGE. In accord with our previous studies (Harrington et al., 1985; Drozdo and Pledger, 1991; Olashaw et al., 1991; Coats et al., 1994) , PDGF receptor activation induced by PDGF treatment in vivo could be visualized by incubation of immune complexes with [g-32 P]ATP in vitro (Figure 4, lanes 2 and 4) . In addition, in vitro PDGF-dependent phosphorylation of Stat3 was also evident, regardless of whether Stat3 was directly immunoprecipitated (along with activated PDGF receptors, lane 4) or was co-precipitated by antibody to the PDGF b receptor (lane 2; arrow indicates where Stat3 runs on gel). These data demonstrate that Stat3 is phosphorylated at tyrosine while complexed to the PDGF receptor by a kinase that is present in the complex.
Involvement of Src in Stat3 activation by PDGF
Although the data presented in Figure 4 are consistent with a model of Stat3 activation involving its direct phosphorylation by activated PDGF receptors, they do not exclude the possibility of Stat3 phosphorylation by a receptor-associated kinase. As c-Src is activated by PDGF (Ralston and Bishop, 1985; Gould and Hunter, 1988) , and has been shown previously to activate Stat3 (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997) , we examined the involvement of Src family kinases (referred to as Src) in Stat3 activation by PDGF in Balb/c-3T3 cells. Initial experiments assessed the capacity of Src to interact with the PDGF b receptor and Stat3. The Src antibody used in these studies recognizes the three Src family members (c-Src, c-Yes and c-Fyn) present in Balb/c-3T3 cells (Kypta et al., 1990) . As demonstrated by co-precipitation analysis, (Kypta et al., 1990) , Src associated with PDGF b receptors in a PDGF-dependent manner (Figure 5a ). Although a small amount of receptor was co-precipitated by the Src antibody from extracts of untreated cells, Src/receptor interaction increased substantially in response to PDGF.
To demonstrate that Src was present in receptor complexes that also contained Stat3, the eect of receptor immunodepletion on Src/Stat3 interaction was determined. Immunodepletion was accomplished by incubation of extracts of PDGF-treated cells with antibody to the PDGF b receptor, and subsequent removal of immune complexes with protein A agarose. As shown in Figure 5b (top panel), this treatment eectively reduced the amount of receptor present in the extract. On the other hand, most (although not all) of the Stat3 was present in immunodepleted extracts (middle panel), thus suggesting that only a small percentage of the Stat3 population associates with the PDGF b receptor at any given time. Control and receptor-depleted extracts were then immunoprecipitated with antibody to Src, and Src immunoprecipitates were immunoblotted with antibody to Stat3. Antibody to Src co-precipitated Stat3 from control extracts, and the amount of co-precipitated Stat3 was reduced substantially by receptor depletion (bottom panel). Thus, removal of PDGF b receptors also removes Srcassociated Stat3, indicating that all three proteins are present in the same complex. The small amount of Stat3 co-precipitated by the Src antibody from depleted extracts (bottom panel) may re¯ect residual levels of receptors in these extracts (top panel). Alternatively, Src and Stat3 may also interact with PDGF a receptors which, albeit at lower levels than b receptors, are also expressed in Balb/c-3T3 cells (Drozdo and Pledger, 1991; Bazenet et al., 1996) .
The existence of Src and Stat3 in the same receptor complexes suggests that these proteins are in close proximity and thus that Src may contribute to Stat3 activation. To directly test the requirement for Src in Stat3 activation by PDGF, density-arrested Balb/c-3T3 cells were pretreated with or without the Src kinase inhibitor, PD180970 (at 1 mM), and subsequently exposed to PDGF for 30 min in the presence or absence of inhibitor; whole-cell extracts were prepared and analysed for hSIE binding activity by EMSA. PD180970 is a member of a group of inhibitors that speci®cally inhibits the kinase activity of Src family members when used at appropriate concentrations (for PD180970, less that than 5 mM; Allgayer et al., 1999; Roginskaya et al., 1999; Kraker et al., submitted) . As shown in Figure 6a , three hSIE binding activities, corresponding to Stat3/3, Stat1/3 and Stat1/1 complexes, were evident in cells receiving PDGF alone, and activation of all three was abolished by co-treatment of cells with PD180970. Thus, Src kinase activity is required for the activation of both Stat3 and Stat1 in PDGF-treated cells. This ®nding, coupled with data demonstrating interaction of Src with Stat3 ( Figure  5b ), suggests that Stat3 may be a direct substate of Src.
As speci®city controls for PD180970, we also monitored its eect on: (1) PDGF activation of MAPK, and (2) interleukin 6 (IL-6) activation of Stat3. MAPK activity was determined by Western blotting of cell extracts with an antibody that speci®cally recognizes phosphorylated, and thus activated, p42 and p44 MAPK. As presented in Figure 6c , PDGF activated MAPK to similar extents in the presence and absence of PD180970, thus indicating that the activity of the PDGF receptor was unimpaired by the inhibitor. Total amounts of p42 and p44 MAPK were similar for all treatments (data not shown). Since activation of Stat3 by IL-6 is mediated by JAK kinases (Catlett-Falcone et al., 1999) , the limited eect of PD180970 on this process (Figure 6b ) excludes these kinases as targets of PD180970.
Requirement of Src kinase activity for cell cycle traverse
The eect of PD180970 on DNA synthesis was also determined. Density-arrested Balb/c-3T3 cells were pretreated with 1 mM PD180970, and subsequently stimulated with 10 ng/ml PDGF and 5% serum for 20 h. Cells were harvested for propidium iodide staining and their position in the cell cycle was identi®ed by¯ow cytometry. The data presented in Figure 7 clearly show that PD180970 blocks the capacity of cells to enter S phase in response to PDGF+serum. In the absence of PD180970, 64% of the quiescent population entered DNA synthesis when exposed to PDGF+serum; in contrast, when treated with PDGF+serum+PD180970, essentially all cells (92%) remained in G 1 . Whether the requirement of Src activity for the PDGF-mediated cell cycle traverse of density-arrested Balb/c-3T3 cell re¯ects its capacity to activate STATs is not known at present. 
Discussion
In agreement with previous ®ndings (Wagner et al., 1990) , our data show that PDGF rapidly and transiently activates Stat1 and Stat3 in density-arrested Balb/c-3T3 ®broblasts (Figure 1 ). Activation was demonstrated by EMSA analysis using an hSIE probe, and by monitoring the nuclear accumulation and tyrosine phosphorylation of Stat3. PDGF activation of Stats 1 and 3 (or of SIF complexes) has been described previously for several cell types including ®broblasts (Wagner et al., 1990; Silvennoinen et al., 1993; Cirri et al., 1997) , smooth muscle cells (Yamamoto et al., 1996; Marrero et al., 1997) , and mesengial cells (Choudhury et al., 1996) , and the capacity of PDGF to activate Stats 5 and 6 has also Balb/c-3T3 cells were incubated overnight in spent medium containing 1 mM PD180970. Pretreated and untreated cells then received either no addition or 10 ng/ml PDGF for 30 min at 378C. Nuclear extracts were analysed by EMSA using the hSIE probe (a), and cytosolic extracts were immunoblotted with an antibody that recognizes activated p42 and p44 MAPK (b). (c) Balb/c-3T3 cells were pretreated with PD180970 as above, and subsequently exposed to 10 ng/ml IL-6 for 30 min at 378C. Nuclear extracts were analysed by EMSA using the hSIE probe been reported (Patel et al., 1996; Valgeirsdottir et al., 1998) . The mechanism by which PDGF activates the STAT proteins is, however, unclear and, based on current paradigms of RTK/substrate interaction, is thought to involve the ligand-dependent association of STAT SH2 domains with speci®c receptor phosphotyrosine residues, and the consequent phosphorylation and activation of STAT proteins by the receptor itself or by accessory kinases such as Src or JAKs (Vignais et al., 1996; Valgeirsdottir et al., 1998; Vignais and Gilman, 1999) . Our studies suggest an alternative model of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is phosphorylated and activated.
In support of our model, we ®nd that PDGF induces the phosphorylation of Stat3 at Tyr 705 when presented to cells at 48C (Figure 2a ). While this observation does not necessarily imply pre-association of Stat3 with PDGF receptors, it does suggest that these proteins are at least in close proximity. A similar conclusion was reached by Silvennoinen et al., (1993) , who observed induction of SIF DNA-binding activity in human ®broblasts treated with PDGF at 48C. More direct evidence of pre-assembled Stat3/PDGF receptor complexes was obtained from immunoprecipitation/ immunoblot experiments in which antibody to the PDGF b receptor (or to Stat3) was shown to coprecipitate comparable amounts of Stat3 (or receptor) from extracts of both stimulated and unstimulated cells (Figures 2b and 3) . The concept of pre-associated Stat/ RTK complexes has also been proposed recently by Olayoiye et al., (1999) , who observed ligand-independent interaction of Stats 1, 3 and 5 with ErbB1 receptors in A431 cells. The mechanism by which the STAT proteins associate with RTKs in the absence or presence of ligand is not known at present. We ®nd that the increase in PDGF receptor autophosphorylation induced by PDGF (Figure 4) is not paralleled by a comparable increase in the amount of receptor-bound Stat3 (Figure 3 ). This observation argues against an interaction of Stat3 SH2 domains with receptor phosphotyrosines (a premise supported by the lack of canonical Stat3 SH2 binding sites in the intracellular domains of these receptors [Yarden et al., 1986; Gronwald et al., 1988; de Konig et al., 1996; Yamanaka et al., 1996; Chakraborty et al., 1999] ), and suggests that Stat3/receptor interaction in unstimulated cells is not due to a low level of basal receptor autophosphorylation. In agreement, Olayoiye et al., (1999) found that mutation of the Stat5 SH2 domain did not impair its capacity to bind ErbB1 receptors in EGF-treated or untreated A431 cells. Ligand-independent association of Stat1 with the IFNAR2C subunit of the interferon-a receptor has also been described, and is thought to be mediated by sequences contained within the N-terminal (non-SH2) region of Stat1 . Thus, via a yet to be determined mechanism, the STAT proteins may interact with both cytokine and polypeptide hormone receptors in the absence of stimulus.
Although association of Stat3 with the PDGF b receptor occurred in the absence of PDGF, tyrosine phosphorylation and activation of Stat3 clearly necessitated exposure of cells to PDGF (Figures 1, 2a  and 3 ). Similarly, as described by others Olayioye et al., 1999) , activation of STAT proteins pre-bound to ErbB1 receptors and interferon receptors was also ligand-dependent. For RTKs, the requirement for ligand apparently re¯ects the need for receptor activity as kinase-de®cient PDGF b receptors do not mediate STAT activation in response to PDGF (Sachsenmaier et al., 1999) . Although necessary, receptor activation in itself was insucient for STAT activation by PDGF; as demonstrated by use of the Src-speci®c inhibitor, PD180970, Src kinase activity was also required (Figure 6 ). Furthermore, similar to ®ndings reported for ErbB1 receptors (Olayioye et al., 1999), we also found that Src associated with Stat3/ PDGF b receptor complexes in PDGF-treated cells (Figure 5b ). It is notable that phosphorylated Src was not evident in in vitro kinases assays ( Figure 4) ; this may be due to the fact that the level of Src phosphorylation is low and cannot be detected without ®rst immunoprecipitating Src. Involvement of Src in PDGF-induced STAT activation is supported by studies demonstrating abrogation of this response by expression of a dominant-negative c-Src variant in NIH3T3 cells (Cirri et al., 1997) , and by mutation of the Src-binding sites (Y579 and Y581) of the PDGF b receptor (Valgeirsdottir et al., 1998; Sachsenmaier et al., 1999) . On the other hand, receptor variants containing mutations in the regions immediately surrounding these phosphotyrosines allowed STAT activation in response to PDGF in the absence of detectable Src kinase activity (Sachsenmaier et al., 1999) . It is possible that low levels of Src activity, sucient for STAT activation, occur in cells expressing these receptor mutants, and thus account for the discrepancy between these results and those obtained by us and others (Olayioye et al., 1999) using inhibitors that presumably completely abolish Src activity. Alternatively, the dierences observed may re¯ect dierences in systems containing endogenous receptors (our study) versus ectopically expressed receptors (Sachsenmaier et al., 1999) . We also note that Balb/c-3T3 cells contain three Src family members, c-Src, c- Figure 7 Requirement of Src kinase activity for PDGFmediated cell cycle traverse. Density-arrested Balb/c-3T3 cells were incubated overnight in spent medium containing 1 mM PD180970. Pretreated and untreated cultures were either harvested at this time (quiescent controls), or refed with medium containing 10 ng/ml PDGF and 5% serum in the presence or absence of 1 mM PD180970. Cells were harvested 20 h after refeeding. Cells were stained with propidium iodide and analysed by¯ow cytometry. It is noted that cells do not enter DNA synthesis in the presence of 5% serum alone (data not shown)
Yes and c-Fyn, all of which bind the same sites on the PDGF b receptor (Kypta et al., 1990) and are presumptive targets of PD180970. As our studies utilized a Src antibody that does not discriminate between the dierent Src family members, our results do not demonstrate a requirement for c-Src per se in Stat3 activation by PDGF. While a role for c-Src is likely, it is possible that c-Yes and c-Fyn also contribute to this response (Kypta et al., 1990) .
Given our ®ndings on the association of Stat3 with both Src and PDGF receptors, and previous studies showing that both kinases phosphorylate Stat3 in vitro (Cao et al., 1996; Vignais and Gilman, 1999) , it is dicult to de®nitively reconcile which kinase actually phosphorylates and thus activates Stat3 in our system. It is possible that Stat3 is phosphorylated by Src, and that the PDGF b receptor simply serves as a scaold to bring Src and Stat3 into proximity. As Src association with PDGF b receptors is ligand-dependent ( Figure  5a ), whereas Stat3 association with these receptors is not (Figures 2b and 3) , it is doubtful that Src plays a role in coupling Stat3 to receptors; thus, a catalytic rather than an adaptor function of Src is likely. In support, Src is thought to be responsible for the phosphorylation of STATs pre-bound to ErbB receptors (Olayioye et al., 1999) . Regardless of the kinase involved, our data demonstrate that Stat3 undergoes rapid phosphorylation and nuclear translocation in response to PDGF. Studies assessing Stat3 status following addition of PDGF to cells showed that similar amounts of Stat3 were co-precipitated by antibody to the PDGF b receptor for times up to 30 min (Figure 3) , and that during this time period, levels of nuclear Stat3 increased progressively ( Figure  1d) . Thus, the accumulation of Stat3 in the nucleus was not mirrored by a reduction in the levels of receptorassociated Stat3. This observation suggests a dynamic model of Stat3 activation in which Stat3 molecules continuously attach to receptors, become phosphorylated, detach, and enter the nucleus. This scenario implies that, relative to receptors, Stat3 molecules are in excess in cells, and in support we have found that considerable amounts of Stat3 are present in cell extracts immunodepleted of PDGF b receptors ( Figure  5b ). This model allows both the rapid activation of Stat3 in response to ligand engagement of the receptor, and the generation of high levels of Stat3 activity.
Various strategies have been employed previously to examine the role of Src activity in PDGF-mediated mitogenesis. Courtneidge and co-workers (TwamleyStein et al., 1993; Barone and Courtneidge, 1995) , for example, microinjected a variety of cell types with neutralizing Src antibodies or dominant-negative c-Src constructs, and found that both treatments abrogated the capacity of PDGF to elicit a proliferative response. As an alternative approach, Broome and Hunter (1996) established ®broblast lines that expressed kinaseinactive c-Src; these cells, like the microinjected cells, were mitogenically unresponsive to PDGF. Rather than directly targeting Src, Kazlauskas and co-workers (DeMali and Kazlauskas, 1998; Gelderloos et al., 1998) attempted to neutralize PDGF-induced Src activation by mutating the Src binding sites on the PDGF receptors. In contrast to the results described above, ablation of Src activity by this method did not impair the capacity of cells to respond proliferatively to PDGF. In our studies, the eect of the Src kinase inhibitor PD180970 on the cell cycle traverse of density-arrested Balb/c-3T3 cells was determined. These cells traverse G 0 /G 1 and enter S phase in response to PDGF in the presence of serum and, as shown in Figure 7 , this process was clearly blocked by PD180970. These ®ndings, in agreement with those of Twamley-Stein et al., (1993) , Barone and Courtneidge (1995) and Broome and Hunter (1996) , indicate that a Src-mediated event(s) is required for the G 0 /G 1 traverse of Balb/c-3T3 cells. As the STAT proteins are activated in a Src-dependent manner, and have been shown to induce the expression of growth regulatory gene products (Bromberg et al., 1999) , it is possible that Src promotes cell cycle traverse via activation of the STAT proteins. A similar scenario has been proposed for myeloid precursor cells in which expression of a dominant-negative c-Src mutant was shown to inhibit both interleukin-3-mediated Stat3 activation and proliferation (Chaturvedi et al., 1998) . Thus, the Src proteins may promote mitogenesis via STAT activation in response to both polypeptide hormones and speci®c cytokines. Furthermore, dominant-negative Stat3 mutants have been shown to block cell transformation by the Src oncoprotein (Turkson et al., 1998; Bromberg et al., 1999) .
Materials and methods
Cell culture
Balb/c-3T3 cells (clone A31) were cultured in Dulbecco-Vogt modi®ed Eagle's medium supplemented with 10% calf serum, 4 mM L-glutamine, 50 units/ml penicillin and 50 mg/ml streptomycin in a humidi®ed atmosphere containing 5% CO 2 . For experiments, cells were grown to con¯uence and used 2 ± 3 days after growth cessation.
Preparation of nuclear extracts and total cell lysates
For determination of STAT nuclear translocation, crude nuclei were isolated as described previously (Olashaw and Pledger, 1983) . Cells were rinsed with and scraped into phosphate-buered saline (PBS), pelleted, and resuspended in reticulocyte standard buer (RSB; 10 mM NaCl, 15 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4). Cells were disrupted by passage through a 22 gauge needle and centrifuged at 500 g, and the nuclear pellet was rinsed twice with RSB. Whole-cell lysates were prepared by incubating cell pellets for 30 min at 48C in immunoprecipitation buer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethysulfonyl¯uoride, 5 mM NaF, 100 mM sodium orthovanadate, and 5 mg/ml leupeptin). Insoluble material was removed by centrifugation, and lysates were aliquoted and stored 1 ± 15 days at 7808C.
Electrophoretic mobility shift assay (EMSA)
EMSA analysis was performed on whole-cell extracts prepared as outlined above or on nuclear extracts prepared as described previously (Yu et al., 1995) . For EMSA analysis, an oligonucleotide containing a high anity variant of the serum-inducible element (SIE) of the c-fos promoter was used (hSIE; 5'-AGCTTCATTTCCCGTAAATCCCTAAAGCT; Wagner et al., 1990) ; this variant binds Stat1 and Stat3. The oligonucleotide was annealed to its complementary strand, and radiolabeled by incubation with Klenow enzyme and [a-32 ]deoxynucleotide triphosphates. Whole-cell lysates (10 mg) were incubated in DNA-binding buer (10 mM KCl, 10 mM EDTA, 0.5 mg/ml BSA, 0.1 mg/ml poly [dI : dC], 50% glycerol) containing 10 fmol hSIE probe for 30 min at room temperature. Reaction mixtures were electrophoresed on 5% polyacrylamide gels in 50 mM Tris/44 mM borate/0.5 mM EDTA. Following electrophoresis, gels were dried and exposed to ®lm for visualization of radiolabeled DNA/ protein complexes. In some experiments, cell extracts were incubated with antibody to Stat1 or Stat3 for 20 min at room temperature before addition of the probe.
Immunoprecipitation and kinase assay
Cell lysates containing equivalent amounts of protein were incubated with antibody for 2 h at 48C, and subsequently with protein A agarose for 1 ± 2 h at 48C. Immune complexes were washed with kinase buer (50 mM HEPES pH 7.4, 10 mM MgCl 2 , 5 mM MnCl 2 , 10 mM dithiothreitol), and incubated in kinase buer supplemented with 10 mM ATP and 1 mCi [g-32 P]ATP for 30 min at 308C. Reactions were stopped by heating in Laemmli buer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% sodium dodecyl sulfate, 2% bmercaptoethanol, 0.05% bromophenol blue), and proteins were resolved on 8% SDS ± polyacrylamide gels. Radiolabeled proteins were visualized by autoradiography.
Western blotting (immunoblotting) analysis
Whole-cell or nuclear extracts were normalized for protein, and heated at 958C for 5 min in Laemmli buer. Proteins were resolved on 8% SDS-polyacrylamide gels, and electrophoretically transferred to nitrocellulose or polyvinylidene di¯uoride membranes in a semi-dry blotting system. Membranes were blocked in phosphate-buered saline supplemented with 5% instant milk and 0.1% Tween-20, and incubated with antibody for 1 h at room temperature. Proteins recognized by the antibody were detected by enhanced chemiluminescence using a horseradish peroxidase-coupled secondary antibody. In some experiments, cell lysates were immunoprecipitated as described above, and Western blot analysis was performed on immune complexes.
Flow cytometry
Cells were removed from the plates with 0.125% trypsin and 0.5 mM EDTA in PBS; an equal volume of medium containing 10% serum was added to neutralize the trypsin. Cells were pelleted and resuspended in PBS (1 ml), and 95% ethanol (4 ml) was added slowly. Following incubation at 48C for a minimum of 16 h, cells were pelleted and resuspended in PBS containing 0.1% Tween-20, 0.05% bovine serum albumin, 10 mg/ml RNase A and 50 mg/ml propidium iodide. After a further incubation at 48C for at least 4 h, cell cycle distribution was determined with a Becton Dickinson FACScan.
Materials
PDGF-BB was purchased from Biosource International, Camarillo CA, USA. Antibodies to Stat1, Stat3, the PDGF b receptor, and Src family members were obtained from Santa Cruz Biotechnologies, Santa Cruz CA, USA. Antibody to phosphotyrosine was purchased from UBI, Lake Placid NY, USA. Antibody to Tyr 705-phosphorylated Stat3 was from New England Biolabs, Beverly MA, USA, and antibody to phosphorylated MAPK was from Pro-mega, Madison WI, USA.
